Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Achieve Life Sciences, and Actinium Pharma

PRNewswire 26-Apr-2018 6:15 AM

Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Achieve Life Sciences, and Actinium Pharma

PR Newswire

NEW YORK, April 26, 2018 /PRNewswire/ -- strives to bring the best free research to the investment community.  Today we are offering reports on XXII, ABEO, ACHV, and ATNM which can be accessed for free by signing up to has initiated research coverage on 22nd Century Group Inc. (NYSE AMER: XXII), Abeona Therapeutics Inc. (NASDAQ:ABEO), Achieve Life Sciences Inc. (NASDAQ:ACHV), and       . (NYSE AMER: ATNM). Biotechnology companies are engaged in the research and development of biological substances, primarily for the purpose of drug discovery and diagnostic development. All you have to do is sign up today for this free limited time offer by clicking the link below.

22nd Century Group

On Wednesday, shares in Williamsville, New York headquartered 22nd Century Group Inc. recorded a trading volume of 1.71 million shares. The stock ended the session 3.90% higher at $2.13. The Company's shares have gained 46.90% in the past twelve months. The stock is trading below its 50-day moving average by 14.53%. Moreover, shares of 22nd Century, which provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding, have a Relative Strength Index (RSI) of 38.36.

On April 23rd, 2018, 22nd Century Group announced that the Food and Drug Law Institute has published an article by the Company's Senior Vice President of Science and Regulatory Affairs, Dr. James Swauger. In this matter-of-fact public policy analysis, Dr. Swauger points out that since it is universally accepted that nicotine is the primary addictive component of cigarettes, the Tobacco industry and public health officials should logically support the nicotine reduction plan proposed by the US FDA. Get the full research report on XXII for free by clicking below at:

Abeona Therapeutics

Dallas, Texas-based Abeona Therapeutics Inc.'s stock closed the day 6.23% lower at $17.30 with a total trading volume of 1.28 million shares, which was above their three months average volume of 1.25 million shares. The Company's shares have advanced 14.95% in the past month, 12.34% in the previous three months, and 217.43% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 12.66% and 19.42%, respectively. Additionally, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases, have an RSI of 50.18.

On April 02nd, 2018, Abeona Therapeutics announced the appointment of Carsten Thiel, Ph.D., as CEO. Timothy J. Miller, Ph.D., will remain President and assume the position of Chief Scientific Officer, in charge of the Company's expanding clinical and preclinical research programs. Access the free research report on ABEO now by signing up at:

Achieve Life Sciences

Bothell, Washington headquartered Shares in Achieve Life Sciences Inc. recorded a trading volume of 17,578 shares. The stock ended yesterday's trading session 2.26% lower at $1.30. The Company's shares have advanced 2.36% in the past month. The stock is trading below its 50-day moving average by 3.05%. Furthermore, shares of the Company, which develops and commercializes therapies that address treatment resistance in cancer patients, have an RSI of 46.71. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ACHV at:

Actinium Pharmaceuticals

New York-based Actinium Pharmaceuticals Inc.'s stock finished Wednesday's session 0.20% higher at $0.34 with a total trading volume of 577,115 shares. The stock is trading below its 50-day moving average by 19.92%. Additionally, shares of Actinium Pharma, which develops targeted therapies for patients with cancers lacking effective treatment options, have an RSI of 30.38.

On March 28th, 2018, Actinium Pharmaceuticals (ATNM) announced that it has entered into a research and option agreement with Astellas Pharma Inc. ("Astellas") to develop Actinium-225 Radio-Conjugates using its Actinium Warhead Enabling (AWE) Platform Technology. Under this collaboration, ATNM will utilize its AWE Platform to conjugate and label selected Astellas targeting agents with the powerful actinium-225 (225Ac) payload. ATNM will also be responsible for conducting preclinical validation studies on the novel ARCs generated. Aspiring Member, please take a moment to register below for your free research report on ATNM at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:

SOURCE Wall St. Equities

Image for Press Release 616936

Wait, Before You Leave...